ClinicalTrials.gg
CompletedNCT00988494Updated Nov 22, 2012

Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

A Phase 2 interventional study of DE-105 ophthalmic solution and DE-105 ophthalmic solution in Persistent Corneal Epithelial Defect, sponsored by Santen Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2012-11-22.

Sponsored by Santen Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

Safety and efficacy of DE-105 ophthalmic solution in patients with persistent corneal epithelial defect will be evaluated. Dose-dependent efficacy will be evaluated as well.

02

Conditions studied

  • Persistent Corneal Epithelial Defect
03

In context

Lead sponsor

Santen Pharmaceutical Co., Ltd. is the lead sponsor of 30 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has corneal epithelial defect and decreased corneal sensitivity.
  • Has undergone continuous treatment for corneal epithelial defect for 1 week or longer.

Exclusion criteria

Exclusion Criteria:

  • Presence of disease such as active ocular infection, or abnormal lid closure.
  • History or presence of chemical burn, Stevens - Johnson Syndrome, etc.
  • History of corneal transplantation, LASIK, or hematopoietic stem cell transplantation.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    High concentration

    DE-105 high concentration

    Drug: DE-105 ophthalmic solution

  • Experimental
    Low concentration

    DE-105 low concentration

    Drug: DE-105 ophthalmic solution

  • Placebo comparator
    Placebo

    DE-105 placebo

    Drug: Placebo ophthalmic solution

Interventions

06

What researchers measure

Primary outcomes

  1. Restoration of corneal epithelial defect

    Time frame: Every week

Secondary outcomes

  1. Visual acuity,etc.

    Time frame: Exit visit,etc.

07

Study locations

1 site
  • Santen study sites
    Osaka, Japan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 22, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00988494
First posted
Oct 2, 2009
Start date
Sep 2009
Last update
Nov 22, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Spinosad

Start the discussion